
KYOTO -- Takara Bio will ramp up its domestic capacity to produce reagents for PCR tests to 8 million specimens a month, eight times more than the current level, as early as this summer.
Japan government to support drugmaker to prevent supply disruption amid pandemic
KYOTO -- Takara Bio will ramp up its domestic capacity to produce reagents for PCR tests to 8 million specimens a month, eight times more than the current level, as early as this summer.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.